Literature DB >> 10588330

Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies.

F Zoulim1.   

Abstract

Chronic hepatitis B infection remains a major public health problem worldwide. The hepatitis B virus belongs to the family of hepadnaviruses that replicate their DNA genome via a reverse transcription pathway. The chronicity of infection in infected hepatocytes is maintained by the persistence of the viral covalently closed circular DNA. The main strategies to combat chronic HBV infection rely on the stimulation of the specific antiviral immune response and on the inhibition of viral replication. While the prolonged administration of reverse transcriptase inhibitors is most often associated with a control of viral replication rather than eradication, it may select for resistant mutants. The search for new viral targets is therefore mandatory to design combination strategies to prevent the emergence of resistant mutants and eventually clear viral infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588330     DOI: 10.1016/s0166-3542(99)00056-x

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

Review 1.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

2.  Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism.

Authors:  S Urban; S Urban; K P Fischer; D L Tyrrell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

3.  The analysis of correlation between IL-12 gene expression and hepatitis B virus in the affected patients.

Authors:  Abdolhossein Zare; Ahmad Rashki; Sajjad Ghahari; Bashir Ghayoori
Journal:  Virusdisease       Date:  2015-07-07

Review 4.  Current management strategies for hepatitis B in the elderly.

Authors:  P Merle; C Trépo; F Zoulim
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.

Authors:  F Le Guerhier; C Pichoud; C Jamard; S Guerret; M Chevallier; S Peyrol; O Hantz; I King; C Trépo; Y C Cheng; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  Transfer of hepatitis B virus genome by adenovirus vectors into cultured cells and mice: crossing the species barrier.

Authors:  M F Sprinzl; H Oberwinkler; H Schaller; U Protzer
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Inhibition of hepatitis B virus by a novel L-nucleoside, beta-L-D4A and related analogues.

Authors:  Jin-Ming Wu; Ju-Sheng Lin; Na Xie; Kuo-Huan Liang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

8.  Lethiferous effects of a recombinant vector carrying thymidine kinase suicide gene on 2.2.15 cells via a self-modulating mechanism.

Authors:  Quan-Cheng Kan; Zu-Jiang Yu; Yan-Chang Lei; Lian-Jie Hao; Dong-Liang Yang
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

9.  Expression of hepatitis B virus 1.3-fold genome plasmid in an SV40 T-antigen-immortalized mouse hepatic cell line.

Authors:  Xiu-Guang Song; Peng-Fei Bian; Shu-Li Yu; Xiu-Hua Zhao; Wei Xu; Xue-Hui Bu; Xia Li; Li-Xian Ma
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

10.  Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen.

Authors:  Nicoletta Potenza; Umberto Papa; Nicola Mosca; Francesca Zerbini; Valentina Nobile; Aniello Russo
Journal:  Nucleic Acids Res       Date:  2011-02-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.